Jane Healy
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
-
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Papers in
- Oncology 15
- Cancer Immunotherapy and Biomarkers 14
- Colorectal Cancer Treatments and Studies 4
- CAR-T cell therapy research 3
- Co-authors
- Vann Bennett (6 shared papers)Talia Golan (3 shared papers)Sandeep S. Davé (5 shared papers)Jiaxin Niu (4 shared papers)Kathryn F. Mileham (5 shared papers)Elliot Chartash (3 shared papers)Corinne Maurice‐Dror (3 shared papers)Hyun Cheol Chung (3 shared papers)
- Journals
- Blood (5 papers)Annals of Oncology (5 papers)Cancer Research (4 papers)Journal of Clinical Oncology (2 papers)Science Signaling (1 paper)
- Partner nations
- United StatesSouth KoreaIsrael
In The Last Decade
Jane Healy
26 papers receiving 825 citations
Jane Healy's Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 320
- Immunology 198
- Cell Biology 128
- Physiology 177
- Developmental Neuroscience 18
Countries citing papers authored by Jane Healy
This map shows the geographic impact of Jane Healy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Healy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Healy more than expected).
Fields of papers citing papers by Jane Healy
This network shows the impact of papers produced by Jane Healy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Healy. The network helps show where Jane Healy may publish in the future.
Co-authors
The 25 scholars most cited alongside Jane Healy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ Hit paper breakdown → | 2021 | 209 |
| 2 | 2009 | 157 | |
| 3 | 2007 | 152 | |
| 4 | 2016 | 46 | |
| 5 | 2021 | 40 | |
| 6 | 2010 | 32 | |
| 7 | 2007 | 31 | |
| 8 | 2020 | 26 | |
| 9 | 2015 | 26 | |
| 10 | 2004 | 24 | |
| 11 | 2020 | 19 | |
| 12 | 2015 | 15 | |
| 13 | 2024 | 9 | |
| 14 | 2022 | 8 | |
| 15 | 2016 | 8 | |
| 16 | 2019 | 6 | |
| 17 | 2019 | 5 | |
| 18 | 2022 | 5 | |
| 19 | 2023 | 3 | |
| 20 | 2019 | 3 |
About Jane Healy
Jane Healy is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine, having authored 32 papers that have together received 833 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (14 papers), Colorectal Cancer Treatments and Studies (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Pancreatic function and diabetes (4 papers), Cancer Genomics and Diagnostics (3 papers), CAR-T cell therapy research (3 papers), Erythrocyte Function and Pathophysiology (3 papers) and Endometriosis Research and Treatment (2 papers). The work is most often cited by research in Oncology (320 citations), Immunology (198 citations), Cell Biology (128 citations), Physiology (177 citations) and Developmental Neuroscience (18 citations). Jane Healy has collaborated with scholars based in United States, South Korea and Israel. Frequent co-authors include Vann Bennett, Talia Golan, Sandeep S. Davé, Jiaxin Niu, Kathryn F. Mileham, Elliot Chartash, Corinne Maurice‐Dror, Hyun Cheol Chung, D.H. Lee and Mark Voskoboynik. Their work appears in journals such as Blood, Annals of Oncology, Cancer Research, Journal of Clinical Oncology and Science Signaling.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.